Drug Discovery for Neurodegenerative Disease

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 December 2018)

Special Issue Editors

Centro de Investigaciones Biológicas-CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain
Interests: drug design; chemioinformatic; Alzheimer´s diseases; neurodegenerative disorders; cannabinoid
Instituto de Química Médica-CSIC, Juan de la Cierva, 6, 28100 Madrid, Spain
Interests: drug design; chemioinformatic; Alzheimer´s diseases; neurodegenerative disorders; cannabinoid

Special Issue Information

Dear Colleagues,

Disorders associated with the ageing are costly, from both economic and human viewpoints. Among these disorders, neurodegenerative diseases, such as dementia, are attracting a great deal of interest due to their irreversibility, lack of effective treatment, and accompanied social and economic burdens.

In fact, dementia is not a disease, it is a general concept that encompasses a group of symptoms that may be caused by several brain disorders. Therefore, it is important to find out the disease and the mechanisms that may be responsible for these symptoms. Alzheimer’s disease is the leading cause of dementia, accounting for 60–80% of cases, although there are others as serious and important as Alzheimer's, such as Lewy Body Disease/Dementia with Lewy Bodies (DLB) or Vascular Dementia.

In this Special Issue, we would like to try collect different aspects of this set of disorders, including novel therapeutic mechanisms, drug designs and therapeutic options (pharmacology and non-pharmacology treatments). Authors are invited to submit original and review articles on ageing-neurodegenerative diseases that contribute to the understanding of the involved mechanism, novel drug targets, drug design and pharmacology and non-pharmacology therapies for the treatment of these diseases, for publication in this Special Issue of Pharmaceuticals.  

Dr. Nuria E. Campillo
Dr. Juan A. Páez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ageing disorders
  • neurodegenerative diseases
  • drug design
  • Alzheimer's disease
  • dementia

Related Special Issues

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop